TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Apotex Corp. Introduces Injectable Teriparatide for Osteoporosis Treatment in the United States

Wednesday, November 22, 2023

Today, Apotex Corp. has unveiled the release of Teriparatide Injection, a pre-filled pen designed for single-patient use in treating osteoporosis within the United States.

The Teriparatide Injection is supplied as a pre-filled pen with a concentration of 250 mcg/mL, offering 28 daily doses of 20 mcg per pen.

For comprehensive details on Warnings and Precautions, Adverse Reactions, and Contraindications, please refer to the complete Prescribing Information available here. Additionally, it is crucial to review the Medication Guide, accessible here.

Michael Bohling, Vice President of Sales and Marketing at Apotex Corp., emphasizes the importance of this product launch, stating, "Osteoporosis affects approximately 10 million Americans, with millions more facing the risks of low bone density. The introduction of this product will ensure much-needed, affordable access for these patients."

Kiran Krishnan, PhD, Senior Vice President of Global Regulatory Affairs at Apotex Corp., highlights the approval of Teriparatide Injection as a demonstration of Apotex's dedication to developing complex generic drugs, aiming to broaden patient access to cost-effective, high-quality medications.

Ambio, serving as an exclusive co-development partner to Apotex, played a pivotal role in the project's success, leveraging their extensive experience in peptides. Chris Bai, CEO at Ambio, underscores Ambio's strength in developing complex peptides through the approval of Teriparatide bioequivalent.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit